References
- Ackerman DL, Greenland S, Bystritsky A, Small G: Side ef-fects and time course of response in a placebo-controlled trial of fluoxetine for the treatment of geriatric depression. J Clin Psychopharmacol 2000; 20:658–665
- Dittman RW, Linden M, Osterheide M, Schaa B, Ohnmacht U, Weber HJ: Antidepressant drug use: Differences between psychiatrists and general practitioners. Results from a drug uti-lization observation study with fluoxetine. Pharmacopsychia-try 1997; 30:28–34
- Linden M, Gothe H, Dittman RW, Schaaf B: Early termination of antidepressant drug treatment. J Clin Psychopharrnacology 2000; 20:523–530
- Greenberg RP, Bornstein RF, Zborowski MJ, Fisher S, Greenberg MD: A meta-analysis of fluoxetine outcome in the treatment of depression. J Nerv Ment Dis 1994; 182:547–551
- Spitzer RL, Williams JB, Gibbon M, First, MB: Structured Clinical Interview for DSM-III-R-Patient edition (SCID-P). New York: New York State Psychiatric Institute, Biometrics Research Department; 1989
- Hamilton M: A rating scale for depression. J Neurol NeurosurgPsychiatry 1960; 23:56–62
- Denninger J, Mahal Y, Merens W, Alpert JE, Nierenberg AA, Yeung A, Fava M: The Relationship Between Somatic Symp-toms and Depression. American Psychiatric Association An-nual Meeting, Philadelphia, 2002
- Dunn 0J: Multiple comparisons among means. J Am Stat As-soc 1961; 56:52–64
- Beasley CM, Jr, Nilsson ME, Gonzales JS: Efficacy, adverse events, and treatment discontinuations in fluoxetine clinical studies of major depression: A meta-analysis of the 20 mg dose. J Clin Psychiatry 2000:61:722–728
- Benkert O, Szegeli A, Wetzel H, Staab HJ, Meister W, Phillipp. M: Dose escalaton vs. continued doses of paroxetine and maprotiline: A prospective study in depressed out-patients with inadequate treatment response. Acta Psychiatr Scand 95:288–296
- Beasley CM, Bosomworth JC, Wernicke JF: Fluoxetine: Re-lationships among dose, response, adverse events, and plasma concentrations in the treatment of depression. Psychopharma-col Bull 1990:26:18–24